²¹²Pb: Production Approaches and Targeted Therapy Applications

Area of Science:

• Nuclear medicine
• Radiopharmaceutical chemistry
• Oncology

Background:

• Targeted alpha therapy (TAT) is a highly effective cancer treatment modality.
• Lead-212 (²¹²Pb) is a promising radionuclide for TAT due to its suitable half-life and alpha-emitting daughters.
• Efficient preparation of ²¹²Pb-based radiopharmaceuticals is critical for clinical success.

Purpose of the Study:

• To review methods for isolating Lead-212 (²¹²Pb) from its parent radionuclide.
• To discuss molecules for lead binding and the radiochemical characteristics of ²¹²Pb-labeled compounds.
• To present preclinical and clinical trial data for ²¹²Pb-based targeted radiopharmaceuticals.

Main Methods:

• Review of chromatographic, solution, and other techniques for ²¹²Pb isolation.
• Analysis of lead-binding molecules and radiolabeling strategies.
• Compilation of data from preclinical studies and initiated clinical trials.

Main Results:

• Various methods exist for milking ²¹²Pb from radionuclide generators.
• Radiochemical features and stability of ²¹²Pb-labeled compounds are crucial for efficacy.
• Preclinical data support therapeutic and tolerant doses, with clinical trials underway.

Conclusions:

• Lead-212 is a viable option for targeted alpha therapy.
• Optimized radiopharmaceutical preparation is key to maximizing therapeutic benefits.
• Ongoing clinical trials will further establish the role of ²¹²Pb in cancer treatment.